NEW YORK – Clifford Chance has appointed Bryan Luchs as a partner in its U.S. Corporate M&A practice, enhancing the firm’s capabilities in healthcare and life sciences transactions.
Luchs joins Clifford Chance from White & Case, bringing over 28 years of experience representing acquirers, targets, boards of directors, special committees, investors, and investment banks in complex domestic and cross-border transactions, including negotiated and unsolicited public and private M&A deals. His deep expertise in the pharmaceuticals and biotechnology sectors further bolsters the firm’s expanding healthcare and life sciences M&A practice.
Sarah Jones, Global Head of Corporate, stated:
“We are excited to welcome Bryan to our growing U.S. M&A practice. His strong ties to the healthcare and life sciences sector will add significant value to our clients in the U.S. and across the globe.”
Ben Sibbett, Americas Head of Corporate, added:
“Bryan’s experience in M&A, especially in biotech and pharma, will be beneficial as the industry continues to explore new avenues of innovation and growth. We are excited to have him join us and bring this value to clients during this transformative time.”
Bryan Luchs commented:
“I’m extremely pleased by the opportunity to join Clifford Chance – not only to work with such a collaborative team but also to partner with my global counterparts to expand our M&A offering for clients in the U.S.”
Luchs is the firm’s sixth senior hire in the U.S. in 2025, following the arrivals of structured finance counsel Stuart Stahl, commercial litigation partner Peter Isajiw, national security and trade compliance partner Karalyn Mildorf, U.S. project financing partner Gianluca Bacchiocchi, and structured finance partner Joanna Nicholas.
About Bryan Luchs
- Joins Clifford Chance from White & Case.
- Advises on domestic and international M&A transactions, with a strong track record in the pharmaceuticals and biotechnology sectors.
- Representative matters include advising:
- Lantheus Holdings, Inc. (NASDAQ: LNTH) on its acquisition of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX).
- Hikma Pharmaceuticals PLC on its $2.65 billion acquisition of U.S.-based Roxane Laboratories and Boehringer Ingelheim Roxane from Boehringer Ingelheim.
- DFP Healthcare Acquisitions Corp. (NASDAQ: DFPH) on its $842 million business combination with The Oncology Institute.
- Deerfield Healthcare Technology Acquisitions Corp. (NASDAQ: DFHT) on its $614 million business combination with CareMax Medical Group, L.L.C. and IMC Medical Group Holdings LLC.
- Omnicare, Inc. on its $12.7 billion acquisition by CVS Health, as well as prior unsolicited acquisitions of NeighborCare Inc. ($1.8 billion) and NCS HealthCare, Inc. ($460 million).
- Earned BA from Pepperdine University (1988), MA from University of Pennsylvania (1997), and JD from University of Pennsylvania Law School (1996).
- Admitted as an Attorney-at-Law in New York (1999).
